BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
80.96
-0.42 (-0.52%)
At close: Nov 20, 2026, 4:00 PM EST
81.12
+0.16 (0.20%)
After-hours: Nov 20, 2026, 7:42 PM EST
BioNTech SE Revenue
BioNTech SE had revenue of 1.32B EUR in the quarter ending September 30, 2026, a decrease of -14.62%. This brings the company's total for the last twelve months to 2.55B, up 1,160.29% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth. That makes BioNTech SE the 4,057th largest company in the world by revenue and 1,111th in the United States.
Revenue (ttm)
2.55B EUR
Revenue Growth
+1,160.29%
P/S Ratio
7.30
Revenue / Employee
327,219 EUR
Employees
7,807
Market Cap
20.07B USD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BioNTech SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 6.01B |
| Alnylam Pharmaceuticals | 5.01B |
| Jazz Pharmaceuticals | 4.72B |
| Genmab | 4.30B |
| BioMarin Pharmaceutical | 3.66B |
| Exelixis | 2.50B |
| Insmed | 1.52B |
| Ascendis Pharma | 1.37B |
BNTX News
- 2 days ago - BioNTech price target raised to $93 from $92 at JPMorgan - TheFly
- 8 days ago - BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy. - Barrons
- 12 days ago - BioNTech price target lowered to $110 from $130 at H.C. Wainwright - TheFly
- 17 days ago - BioNTech price target lowered to $106 from $114 at Morgan Stanley - TheFly
- 17 days ago - BioNTech price target lowered to $108 from $114 at BofA - TheFly
- 17 days ago - BioNTech price target lowered to $125 from $135 at UBS - TheFly
- 18 days ago - BioNTech SE Earnings Call Transcript: Q3 2026 - Transcripts
- 18 days ago - BioNTech SE Earnings release: Q3 2026 - Filings